Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy in Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
NCT06084897Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 1-year overall survival probability. Started Oct 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06084897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084897.